Dr John Vandermeide
Casual Senior Research Assistant & Postdoctoral Research Fellow
Frazer Institute
Journal Articles
Melino, Michelle, Tu, Wen Juan., Bielefeldt-Ohmann, Helle, Proctor, Martina, Ahuja, Taniya, Vandermeide, John, Bain, Amanda L., Nallan, Gahyathiri, Goh, Sal Lee, Prasanna, Thiru, Dahlstrom, Jane E., Miranda, Mariska, Choudhary, Ramesh Kumar., Anandam, Aravind, Chaudhary, Sumit, Seal, Jonathan T., Sinha, Debottam, Zhang, Shaoqian, Nguyen, Tam Hong., Srihari, Sriganesh, Hartel, Gunter, Ives, Amy, Malik, Laeeq, Yip, Desmond, Nottage, Michelle, Eastgate, Melissa and Rao, Sudha (2025). Depleting the action of EZH2 through PI3K-mTOR inhibition to overcome metastasis and immunotherapy resistance in triple-negative breast cancer. Molecular Cancer Therapeutics, 24 (10), 1511-1526. doi: 10.1158/1535-7163.mct-24-0693
Tu, Wen Juan, Melino, Michelle, Dunn, Jenny, McCuaig, Robert D., Bielefeldt-Ohmann, Helle, Tsimbalyuk, Sofiya, Forwood, Jade K., Ahuja, Taniya, Vandermeide, John, Tan, Xiao, Tran, Minh, Nguyen, Quan, Zhang, Liang, Nam, Andy, Pan, Liuliu, Liang, Yan, Smith, Corey, Lineburg, Katie, Nguyen, Tam H., Sng, Julian D. J., Tong, Zhen Wei Marcus, Chew, Keng Yih, Short, Kirsty R., Le Grand, Roger, Seddiki, Nabila and Rao, Sudha (2023). In vivo inhibition of nuclear ACE2 translocation protects against SARS-CoV-2 replication and lung damage through epigenetic imprinting. Nature Communications, 14 (1) 3680, 3680. doi: 10.1038/s41467-023-39341-4
Conference Paper
Friend, John, Melino, Michelle, Tu, Wen Juan, Ahuja, Taniya, Vandermeide, John, Proctor, Martina, Bain, Amanda, Nallan, Gahyathiri, Bielefeldt-Ohmann, Helle and Rao, Sudha (2025). Immunotherapy and PI3K/mTOR inhibition combination to mediate metastasis and immunotherapy resistance in triple-negative breast cancer. San Antonio Breast Cancer Symposium 2024, San Antonio, TX, United States, 10-13 December 2024. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1557-3265.sabcs24-p3-06-27
Thesis
Vandermeide, John (2025). Examining G9a as a target in breast cancer metastasis and treatment resistance. PhD Thesis, School of Biomedical Sciences. doi: 10.5204/thesis.eprints.261088